Hub-and-spoke business models—the use of a central core of business functions with pipeline assets spun out into subsidiary companies—have gained traction for the benefits they can provide in terms of capital efficiency, diversification of risks, and improved access to capital. Eyexora is applying that business model to accelerate the development of therapies for ophthalmic indications. We spoke to Theresa Heah, CEO of Eyexora, about why the hub-and-spoke model is well-suited for the development of ophthalmic therapies, its initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential.